EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, Science, vol.304, pp.1497-500, 2004. ,
Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population, Clin Cancer Res, vol.15, pp.5216-5239, 2009. ,
First-line crizotinib versus chemotherapy in ALK-positive lung cancer, N Engl J Med, vol.371, pp.2167-77, 2014. ,
ALK-Testung beim nicht-kleinzelligen Lungenkarzinom (NSCLC): immunhistochemie (IHC) und/oder Fluoreszenz-in-situ-Hybridisierung (FISH)?, Pneumologie, vol.70, pp.277-81, 2016. ,
Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline, J Clin Oncol, vol.32, pp.3673-3682, 2014. ,
An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators, J Thorac Oncol, vol.9, pp.631-639, 2014. ,
BIRC6-ALK, a Novel fusion gene in ALK break-apart FISH-negative lung adenocarcinoma, responds to crizotinib, J Thorac Oncol, vol.10, pp.37-39, 2015. ,
ALK testing in lung adenocarcinoma: technical aspects to improve FISH evaluation in daily practice, J Thorac Oncol, vol.10, pp.595-602, 2015. ,
Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinibsensitive ALK rearrangement in a patient with metastatic non-smallcell lung cancer, J Thorac Oncol, vol.7, pp.14-16, 2012. ,
Dichotomous ALK-IHC is a better predictor for ALK inhibition outcome than traditional ALK-FISH in advanced non-small cell lung cancer, Clin Cancer Res, vol.23, pp.4251-4259, 2017. ,